Sculptra vs Skin Boosters Seoul | Evidence-Based Guide

There is no single injectable that suits every concern. Sculptra and skin boosters are often marketed together in Seoul, but they are not interchangeable. Sculptra uses poly-L-lactic acid (PLLA) to support gradual collagen formation in deeper tissue. Rejuran PN, Skinvive and Profhilo are used more superficially, with different materials and different evidence, to address aspects of skin quality such as texture, smoothness or hydration.

If the main concern is structural volume loss, a collagen stimulator may be discussed. If the concern is surface texture or hydration, a skin-quality injectable may be more relevant. Some patients may be offered a staged combination, but that does not make every product necessary. The decision should follow an in-person assessment of anatomy, medical history, treatment area, expected benefit, downtime and budget.

Sculptra contains PLLA. It is placed deeper than most skin-quality injectables and is used for gradual structural correction rather than an immediate surface-hydration effect. In a randomized study of 233 participants, PLLA produced longer-lasting correction than human-derived collagen, with follow-up through 25 months (PMID: 20159311).

That study supports durability in the population and indication examined; it does not establish one universal number of sessions or prove that Sculptra is the right choice for every face. Treatment amount, interval and reassessment depend on the area, baseline volume, injection plan and response. Potential adverse effects include swelling, bruising and delayed papules or nodules. Technique and aftercare matter, and results develop over weeks to months rather than immediately.

Rejuran is described as a polynucleotide (PN) injectable. PN and polydeoxyribonucleotide (PDRN) are related DNA-derived materials, but they are not simply two names for the same substance. A 2025 comparison describes differences in chain length, molecular weight and proposed biological roles (PMID: 40871045). PDRN pharmacology (including proposed adenosine A2A signaling) has been studied mainly in regenerative and wound settings (PMID: 28491036). It should not be copied directly into a brand-specific Rejuran claim as though the same mechanism and clinical effect were established.

A 2025 systematic review of injectable PN for aesthetic use found nine studies involving 219 patients. The authors rated the studies low to moderate in quality and called for better trials (PMID: 39645667). Small split-face randomized studies compared PN with polycaprolactone around the eyes (30 participants; PMID: 31680395) and with non-crosslinked hyaluronic acid under the eyes (27 participants; PMID: 32248707). These studies are useful, but they do not support guaranteed outcomes or a universal protocol. A search of the FDA's public databases on 22 July 2026 did not identify a U.S. FDA authorization for Rejuran.

Skinvive by Juvéderm has a specific U.S. approval. The FDA PMA record states that it is indicated for intradermal injection to improve cheek skin smoothness in adults over 21 (FDA P110033/S059). That wording should not be expanded into approval for every facial area or every skin-quality goal. A prospective single-arm study of 131 people reported improved smoothness through six months and hydration through nine months after VYC-12 treatment (PMID: 31749628).

Profhilo is a hybrid high- and low-molecular-weight hyaluronic-acid product. A 64-person open-label study used two sessions four weeks apart and followed participants for 16 weeks; it reported improvement in the measured skin-quality outcomes, while 23% experienced minor temporary local reactions (PMID: 27713647). An open-label study is not the same level of evidence as a blinded controlled trial.

These categories can overlap, but the most expensive or most popular option is not automatically the most appropriate. Ask what problem each proposed injection is intended to solve and what would change if that item were removed from the plan.

Before booking, request the exact product name, treatment area, amount, proposed number of visits, who performs the injections, expected downtime, important risks and a written price. For Rejuran, ask whether the clinic is referring to PN or PDRN and which product-specific evidence supports the claim. For Skinvive, check whether the proposed use matches the FDA-approved cheek-smoothness indication or is an off-label discussion.

Be cautious when a consultation presents a fixed package as necessary before examining you, promises a precise duration, or treats popularity as proof. Published averages cannot predict an individual result. A useful consultation also explains when Sculptra, a skin booster, or no injectable at all would be the better choice.

Sources

1. Narins RS, et al. Injectable poly-L-lactic acid versus human-derived collagen. PMID: 20159311.
2. Chen Y, et al. Comparative analysis of PN and PDRN. PMID: 40871045.
3. Squadrito F, et al. Pharmacological activity and clinical use of PDRN. PMID: 28491036.
4. Dhaliwal S, et al. Polynucleotides in aesthetic medicine: systematic review. PMID: 39645667.
5. Jeong GJ, et al. PN versus polycaprolactone split-face study. PMID: 31680395.
6. Lee YJ, et al. PN versus non-crosslinked hyaluronic acid split-face study. PMID: 32248707.
7. Niforos F, et al. VYC-12 prospective study. PMID: 31749628.
8. Sparavigna A, Tenconi B. Hybrid hyaluronic-acid open-label study. PMID: 27713647.
9. U.S. FDA. Skinvive by Juvéderm, PMA supplement P110033/S059. FDA record.